Construction of Multivalent Antibody scFv Through Cu(I) Catalyzed 1,3-Dipolar Cycloaddition
Single chain fragments (scFv) derived from the small binding domain of parent monoclonal antibodies (MAb) offer pharmacokinetic advantages and target tumor cells more efficiently than MAb. However, methods for producing multivalent scFv have proven to be very challenging. UC Davis researchers have recently developed a novel method to construct divalent scFv through a small linker using 1,3-dipolar cycloaddition chemistry.
This method provides an efficient and controllable way to produce multivalent antibodies for the advancement of scFv against cancer.
This method surpasses previous methods of production, such as using polyvalent proteins and antibodies, which were limited by low throughput and high cost.
|United States Of America||Issued Patent||8,946,391||02/03/2015||2006-340|